(Q38004097)

26 August 2017

Light on the horizont: biologicals in Behçet uveitis (English)

1 reference

26 August 2017

0 references

1 reference

Dicle Hazirolan

1

1 reference

PubMed ID

22520021

26 August 2017

Nicole Stübiger

series ordinal

2

1 reference

PubMed ID

22520021

26 August 2017

Uwe Pleyer

series ordinal

3

1 reference

26 August 2017

20 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

91

1 reference

26 August 2017

4

1 reference

26 August 2017

297-306

1 reference

Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

The tumor necrosis factor ligand and receptor families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Drug-induced lupus erythematosus: incidence, management and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Behçet's disease: ocular effects and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Treatment of sarcoidosis with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Infections and anti–tumor necrosis factor α therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Current concepts in the etiology and treatment of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Successful treatment of genital ulcers with infliximab in Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Ocular features of Behcet's disease: an international collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

The use of interferon alpha in Behçet disease: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Interferon-alpha Induced Sarcoidosis with Cutaneous Involvement along the Lines of Venous Drainage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Autoimmune diseases induced by biological agents: a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Tumor necrosis factor biology in experimental and clinical arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Type I interferons (alpha/beta) in immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Interferon-alpha in the management of patients with Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

A controlled trial of azathioprine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2011.02348.X

10.1111/J.1755-3768.2011.02348.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22520021